Lack of efficacy of echinocandins against high metabolic activity biofilms of Candida parapsilosis clinical isolates

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorTHOMAZ, Danilo Yamamoto
dc.contributor.authorMELHEM, Marcia de Souza Carvalho
dc.contributor.authorALMEIDA JUNIOR, Joao Nobrega de
dc.contributor.authorBENARD, Gil
dc.contributor.authorNEGRO, Gilda Maria Barbaro Del
dc.date.accessioned2020-10-15T14:33:08Z
dc.date.available2020-10-15T14:33:08Z
dc.date.issued2020
dc.description.abstractCandida parapsilosis produces biofilm, which colonizes catheters and other invasive medical devices that are manipulated by health care workers. In previous studies, C. parapsilosis in vitro biofilms have exhibited high resistance rates against conventional antifungals, but susceptibility to both echinocandins and lipid formulations of amphotericin B (lipid complex and liposomal). However, a recent study showed good activity of amphotericin B deoxycholate on the biomass of C. parapsilosis biofilms. Although moderate activity of echinocandins has been demonstrated against low metabolic activity biofilms of C. parapsilosis, few studies have analyzed the action of these drugs on high metabolic activity biofilms. Moreover, high biofilm-forming isolates have been associated with central venous catheter-related fungemia outbreaks and higher mortality rates. Therefore, it is relevant to verify the activity of the main antifungal drugs against high metabolic activity biofilms of C. parapsilosis. Our study aimed to evaluate the in vitro activity of amphotericin B deoxycholate, anidulafungin, caspofungin, and micafungin against high biofilm-forming and high metabolic activity clinical isolates of C. parapsilosis. Our results showed good activity of amphotericin B against C. parapsilosis biofilms, but none of the echinocandin drugs was effective. This suggests that amphotericin B deoxycholate may be a better choice than echinocandins for the treatment of biofilm-associated infections by C. parapsilosis, mainly in countries with insufficient health care resources to purchase lipid formulations of amphotericin B. These results warn of the possibility of persistent catheter-related candidemia caused by high biofilm-forming C. parapsilosis strains when treated with echinocandin drugs.eng
dc.description.indexMEDLINEeng
dc.description.sponsorshipPrograma de Fomento as Atividades de Pesquisa (PROFAP-LIM)
dc.description.sponsorshipCNPq - the National Science and Technology Development Council, in Brazil [455905/2014-2]
dc.description.sponsorshipSao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2018/15491-3]
dc.identifier.citationBRAZILIAN JOURNAL OF MICROBIOLOGY, v.51, n.3, p.1129-1133, 2020
dc.identifier.doi10.1007/s42770-019-00219-7
dc.identifier.eissn1678-4405
dc.identifier.issn1517-8382
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/37725
dc.language.isoeng
dc.publisherSPRINGEReng
dc.relation.ispartofBrazilian Journal of Microbiology
dc.rightsopenAccesseng
dc.rights.holderCopyright SPRINGEReng
dc.subjectCandida parapsilosiseng
dc.subjectBiofilmeng
dc.subjectXTTeng
dc.subjectAmphotericin Beng
dc.subjectEchinocandinseng
dc.subjectAntifungal resistanceeng
dc.subject.otherin-vitro activityeng
dc.subject.otherantifungal susceptibilityeng
dc.subject.otheralbicans biofilmseng
dc.subject.otheramphotericin-beng
dc.subject.othercaspofungineng
dc.subject.othermanagementeng
dc.subject.otheranidulafungineng
dc.subject.otherepidemiologyeng
dc.subject.othercombinationeng
dc.subject.otherinfectionseng
dc.subject.wosMicrobiologyeng
dc.titleLack of efficacy of echinocandins against high metabolic activity biofilms of Candida parapsilosis clinical isolateseng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalMELHEM, Marcia de Souza Carvalho:Univ Fed Mato Grosso do Sul, Sao Paulo, MS, Brazil; Secretary Hlth, Mycol Unit, Adolfo Lutz Inst, Sao Paulo, MS, Brazil
hcfmusp.citation.scopus5
hcfmusp.contributor.author-fmusphcDANILO YAMAMOTO THOMAZ
hcfmusp.contributor.author-fmusphcJOAO NOBREGA DE ALMEIDA JUNIOR
hcfmusp.contributor.author-fmusphcGIL BENARD
hcfmusp.contributor.author-fmusphcGILDA MARIA BARBARO DEL NEGRO
hcfmusp.description.beginpage1129
hcfmusp.description.endpage1133
hcfmusp.description.issue3
hcfmusp.description.volume51
hcfmusp.origemWOS
hcfmusp.origem.pubmed31898245
hcfmusp.origem.scopus2-s2.0-85077609302
hcfmusp.origem.wosWOS:000505377900008
hcfmusp.publisher.cityNEW YORKeng
hcfmusp.publisher.countryUNITED STATESeng
hcfmusp.relation.referenceAlmirante B, 2017, REV ESP QUIM, V30, P355eng
hcfmusp.relation.referenceArendrup MC, 2017, EUCAST E DEF, V9, P1eng
hcfmusp.relation.referenceBouza E, 2015, ANTIBIOTICS-BASEL, V4, P1, DOI 10.3390/antibiotics4010001eng
hcfmusp.relation.referenceCavalheiro M, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00028eng
hcfmusp.relation.referenceClancy CJ, 2016, J FUNGI, V2, DOI 10.3390/jof2010010eng
hcfmusp.relation.referenceCocuaud C, 2005, J ANTIMICROB CHEMOTH, V56, P507, DOI 10.1093/jac/dki269eng
hcfmusp.relation.referenceCornely OA, 2012, CLIN MICROBIOL INFEC, V18, P19, DOI 10.1111/1469-0691.12039eng
hcfmusp.relation.referenceEnoch DA, 2017, METHODS MOL BIOL, V1508, P17, DOI 10.1007/978-1-4939-6515-1_2eng
hcfmusp.relation.referenceEUCAST, 2018, BREAKP TABL INT MICSeng
hcfmusp.relation.referenceFujimoto K, 2018, J INFECT CHEMOTHER, V24, P958, DOI 10.1016/j.jiac.2018.08.011eng
hcfmusp.relation.referenceGarcia-Effron G, 2008, ANTIMICROB AGENTS CH, V52, P2305, DOI 10.1128/AAC.00262-08eng
hcfmusp.relation.referenceMarcos-Zambrano LJ, 2016, MED MYCOL, V54, P155, DOI 10.1093/mmy/myv094eng
hcfmusp.relation.referenceKatragkou A, 2008, ANTIMICROB AGENTS CH, V52, P357, DOI 10.1128/AAC.00856-07eng
hcfmusp.relation.referenceKatragkou A, 2015, CLIN INFECT DIS, V61, pS622, DOI 10.1093/cid/civ746eng
hcfmusp.relation.referenceKovacs R, 2017, J APPL MICROBIOL, V122, P1529, DOI 10.1111/jam.13452eng
hcfmusp.relation.referenceKuhn DM, 2002, ANTIMICROB AGENTS CH, V46, P1773, DOI 10.1128/AAC.46.6.1773-1780.2002eng
hcfmusp.relation.referenceKuhn DM, 2004, EMERG INFECT DIS, V10, P1074, DOI 10.3201/eid1006.030873eng
hcfmusp.relation.referenceLamoth F, 2018, J ANTIMICROB CHEMOTH, V73, pi4, DOI 10.1093/jac/dkx444eng
hcfmusp.relation.referenceLarkin EL, 2018, J ANTIMICROB CHEMOTH, V73, pi73, DOI 10.1093/jac/dkx451eng
hcfmusp.relation.referenceLazzell AL, 2009, J ANTIMICROB CHEMOTH, V64, P567, DOI 10.1093/jac/dkp242eng
hcfmusp.relation.referenceMarcos-Zambrano LJ, 2014, INT J MED MICROBIOL, V304, P1192, DOI 10.1016/j.ijmm.2014.08.012eng
hcfmusp.relation.referenceMelo AS, 2011, MED MYCOL, V49, P253, DOI 10.3109/13693786.2010.530032eng
hcfmusp.relation.referenceMunusamy K, 2018, REV IBEROAM MICOL, V35, P68, DOI 10.1016/j.riam.2017.07.001eng
hcfmusp.relation.referencePappas PG, 2016, CLIN INFECT DIS, V62, P409, DOI 10.1093/cid/civ1194eng
hcfmusp.relation.referencePierce CG, 2008, NAT PROTOC, V3, P1494, DOI 10.1038/nprot.2008.141eng
hcfmusp.relation.referencePrayska M., 2014, MYCOPATHOLOGIA, V177, P19, DOI [10.1007/s11046-014-9727-724436013, DOI 10.1007/S11046-014-9727-7]eng
hcfmusp.relation.referencePrazynska M, 2018, FOLIA MICROBIOL, V63, P209, DOI 10.1007/s12223-017-0555-2eng
hcfmusp.relation.referencePuig-Asensio M, 2014, CLIN MICROBIOL INFEC, V20, pO245, DOI 10.1111/1469-0691.12380eng
hcfmusp.relation.referenceRodrigues CF, 2017, PATHOGENS, V6, DOI 10.3390/pathogens6040062eng
hcfmusp.relation.referenceRodriguez-Cerdeira C, 2019, COLLOID SURFACE B, V174, P110, DOI 10.1016/j.colsurfb.2018.11.011eng
hcfmusp.relation.referenceSilva S, 2017, J FUNGI, V3, DOI 10.3390/jof3010008eng
hcfmusp.relation.referenceSilva S, 2011, TRENDS MICROBIOL, V19, P241, DOI 10.1016/j.tim.2011.02.003eng
hcfmusp.relation.referenceSimitsopoulou M, 2013, ANTIMICROB AGENTS CH, V57, P2562, DOI 10.1128/AAC.02541-12eng
hcfmusp.relation.referenceSingaravelu K, 2014, REV IBEROAM MICOL, V31, P16, DOI 10.1016/j.riam.2013.09.018eng
hcfmusp.relation.referenceSoldini S, 2018, CLIN MICROBIOL INFEC, V24, P771, DOI 10.1016/j.cmi.2017.11.005eng
hcfmusp.relation.referenceSwaminathan S, 2018, INDIAN J MED MICROBI, V36, P87, DOI 10.4103/ijmm.IJMM_17_400eng
hcfmusp.relation.referenceTaff HT, 2013, FUTURE MICROBIOL, V8, P1325, DOI 10.2217/fmb.13.101eng
hcfmusp.relation.referenceTrofa D, 2008, CLIN MICROBIOL REV, V21, P606, DOI 10.1128/CMR.00013-08eng
hcfmusp.relation.referenceValentin A, 2016, J ANTIMICROB CHEMOTH, V71, P3449, DOI 10.1093/jac/dkw316eng
hcfmusp.scopus.lastupdate2024-05-10
relation.isAuthorOfPublication43076010-bb16-49cf-a357-5c5672b9fe3b
relation.isAuthorOfPublication238dc791-e192-4ac8-9bdd-693de40b32cf
relation.isAuthorOfPublication435ea94f-594d-4595-b5f5-1df649516e3c
relation.isAuthorOfPublication4138a245-a806-4228-8aaa-aaecc2c05ca3
relation.isAuthorOfPublication.latestForDiscovery43076010-bb16-49cf-a357-5c5672b9fe3b
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_THOMAZ_Lack_of_efficacy_of_echinocandins_against_high_metabolic_2020.PDF.pdf
Tamanho:
300.56 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/03
Artigos e Materiais de Revistas Científicas - LIM/53
Artigos e Materiais de Revistas Científicas - LIM/56